| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T183 |
0-187 |
Sentence |
denotes |
Teva’s Digihaler™ has been FDA approved for use with ProAir® (albuterol sulfate 117 mcg), AirDuo® (fluticasone propionate and salmeterol), and ArmonAir® (fluticasone propionate) inhalers. |
| T184 |
188-274 |
Sentence |
denotes |
The Digihaler™ contains built-in sensors that records inhalation data with timestamps. |
| T185 |
275-432 |
Sentence |
denotes |
The inhalation data includes parameters that are important for assessing inhaler technique including peak inspiratory flow rate and inhalation duration [27]. |
| T186 |
433-558 |
Sentence |
denotes |
The device is connected via Bluetooth® technology to a companion App that provides information on inhaler use to the patient. |
| T187 |
559-693 |
Sentence |
denotes |
While to date, the efficacy of Digihalers has not been evaluated; one pilot study has shown its ability to predict exacerbations [28]. |
| T188 |
694-783 |
Sentence |
denotes |
Adults with exacerbation-prone asthma (n = 360) used the ProAir® Digihaler™ for 12 weeks. |
| T189 |
784-954 |
Sentence |
denotes |
The Digihaler™ was able to predict asthma exacerbations (defined as need for oral corticosteroids) with an area under the receiver operating characteristic curve of 0.75. |
| T190 |
955-1087 |
Sentence |
denotes |
The most predictive factor was the average number of albuterol inhalations per day during a period of 5 days before an exacerbation. |
| T191 |
1088-1224 |
Sentence |
denotes |
Further developments of the model in larger populations are needed to determine the efficacy of the Digihaler™ to predict exacerbations. |
